# Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

> **NCT00510887** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00510887
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2012-11
- **Final completion:** 2013-09
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low accrual.
- **Last updated:** 2014-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510887, "Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00510887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*